Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Biomea Fusion (BMEA)
NASDAQ:BMEA
Holding BMEA?
Track your performance easily
BMEA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.61 - $20.21
Previous Close$4.23
Volume858.97K
Average Volume (3M)958.54K
Market Cap
$153.29M
Enterprise Value$74.90M
Total Cash (Recent Filing)$87.95M
Total Debt (Recent Filing)$9.57M
Price to Earnings (P/E)―
Beta1.74
Next Earnings
Mar 03, 2025EPS Estimate
-$0.91Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.00
Shares Outstanding36,238,687
10 Day Avg. Volume1,533,700
30 Day Avg. Volume958,538
Standard Deviation0.38
R-Squared0.00470
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)2.01
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.55
Forecast
1Y Price Target
$36.50Price Target Upside762.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Biomea Fusion News
PremiumCompany Announcements
Biomea Fusion Advances Diabetes Treatment with Positive Study Results
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsBiomea announced positive topline results from the Phase 2 COVALENT-111 clinical trial evaluating icovamenib in patients with T2D.
Regulatory MilestonesThe clinical holds for the two ongoing Phase 1/2 clinical trials evaluating BMF-219 in T2D and T1D have been lifted by the FDA.
Safety And TolerabilityIcovamenib was well-tolerated, with no drug discontinuations due to TEAEs, no hypoglycemic events.
Bears Say
Clinical TrialsTwo ongoing Phase 1/2 clinical trials evaluating BMF-219 in diabetes have been placed on full clinical hold by the FDA based on possible drug-induced hepatotoxicity.
Financial PerformanceThe weak share reaction and anticipation of BMEA trading range bound is influenced by the company's present financing overhang.
Program DevelopmentThe AML program is lagging behind primary menin-inhibitor rivals, with RP2D selection anticipated later.
---
Ownership Overview
32.05% Insiders
15.07% Mutual Funds
21.79% Other Institutional Investors
23.00% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BMEA FAQ
What was Biomea Fusion’s price range in the past 12 months?
Biomea Fusion lowest stock price was $3.61 and its highest was $20.21 in the past 12 months.
What is Biomea Fusion’s market cap?
Currently, no data Available
When is Biomea Fusion’s upcoming earnings report date?
Biomea Fusion’s upcoming earnings report date is Mar 03, 2025 which is in 71 days.
How were Biomea Fusion’s earnings last quarter?
Biomea Fusion released its earnings results on Oct 29, 2024. The company reported -$0.91 earnings per share for the quarter, beating the consensus estimate of -$0.944 by $0.034.
Is Biomea Fusion overvalued?
According to Wall Street analysts Biomea Fusion’s price is currently Undervalued.
Does Biomea Fusion pay dividends?
Biomea Fusion does not currently pay dividends.
What is Biomea Fusion’s EPS estimate?
Biomea Fusion’s EPS estimate is -$0.91.
How many shares outstanding does Biomea Fusion have?
Biomea Fusion has 36,238,686 shares outstanding.
What happened to Biomea Fusion’s price movement after its last earnings report?
Biomea Fusion reported an EPS of -$0.91 in its last earnings report, beating expectations of -$0.944. Following the earnings report the stock price went down -14.262%.
Which hedge fund is a major shareholder of Biomea Fusion?
Among the largest hedge funds holding Biomea Fusion’s share is Baker Bros Advisors LP. It holds Biomea Fusion’s shares valued at 21M.
---
Biomea Fusion Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.50 (762.88% Upside)
$36.50 (762.88% Upside)
Blogger Sentiment
Bullish
BMEA Sentiment 75%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 766.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $100.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 4.6%
Last 30 Days ▼ 4.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-69.23%
12-Months-Change
Fundamentals
Return on Equity
-104.51%
Trailing 12-Months
Asset Growth
-50.94%
Trailing 12-Months
Company Description
Biomea Fusion
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The companies lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.
---
BMEA Stock 12 Month Forecast
Average Price Target
$36.50
▲(762.88% Upside)
Technical Analysis
Best Analysts Covering BMEA
1 Year
1 Year Success Rate
2/12 ratings generated profit
1 Year Average Return
-1.10%
reiterated a buy rating 2 months ago
Copying Joseph Catanzaro's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -1.10% per trade.
---